Form 8-K
8-K — CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Accession: 0001477932-26-005805
Filed: 2026-09-25
Period: 2026-09-24
CIK: 0001187953
SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))
Item: Entry into a Material Definitive Agreement
Item: Unregistered Sales of Equity Securities
Item: Financial Statements and Exhibits
Documents
8-K — celz_8k.htm (Primary)
EX-10.1 — STOCK PURCHASE AGREEMENT (celz_ex101.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — FORM 8-K
8-K (Primary)
Filename: celz_8k.htm · Sequence: 1
celz_8k.htm
0001187953false00011879532026-09-242026-09-24iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 24, 2026
Creative Medical Technology Holdings, Inc.
(Exact name of registrant as specified in its charter)
Nevada
000-53500
87-0622284
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification Number)
211 E Osborn Road, Phoenix, AZ 85012
(Address of principal executive offices)
(480) 399-2822
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
CELZ
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On September 24, 2026, Creative Medical Technology Holdings, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Creative Acquisition Corp. (“CAC”), pursuant to which the Company purchased 4,000,000 shares of common stock of BioDefense, Inc. (“BioDefense”) from CAC for an aggregate purchase price consisting of $200,000 in cash and 1,000,000 shares of the Company’s common stock. After giving effect to the transactions under the Purchase Agreement, the Company owns 16,000,000 shares of BioDefense common stock, constituting 80% of the outstanding shares of common stock of BioDefense, and CAC owns 4,000,000 shares of BioDefense common stock, constituting 20% of the outstanding shares of common stock of BioDefense. Timothy Warbington, the President and Chief Executive officer of the Company, is also the Chairman and Chief Executive Officer of CAC and indirectly owns all of its outstanding shares of capital stock.
The shares of common stock of the Company issued to CAC under the Purchase Agreement were issued in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.
Item 3.02 Unregistered Sales of Equity Securities.
The disclosure in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
10.1
Stock Purchase Agreement, dated September 24, 2026, between Creative Medical Technology Holdings, Inc. and Creative Acquisition Corp.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Creative Medical Technology Holdings, Inc.
Date: September 25, 2026
By:
/s/ Timothy Warbington
Timothy Warbington,
Chief Executive Officer
3
EX-10.1 — STOCK PURCHASE AGREEMENT
EX-10.1
Filename: celz_ex101.htm · Sequence: 2
celz_ex101.htm
EXHIBIT 10.1
STOCK PURCHASE AGREEMENT
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into effective as of September 24, 2026, by and between Creative Acquisition Corp. (the “Seller”) and Creative Medical Technology Holdings, Inc. (the “Purchaser”).
W I T N E S S E T H:
WHEREAS, the Seller holds eight million (8,000,000) shares of the common stock, par value $0.0001 per share (“Common Stock”) of BioDefense, Inc. (the “Company”), and the Purchaser owns twelve million shares (12,000,000) of Common Stock of the Company; and
WHEREAS, the Purchaser desires to purchase four million (4,000,000) shares of Common Stock of the Company (the “Shares”) from the Seller, and the Seller desires sell the Shares to the Purchaser, so that after giving effect to such purchase and sale, the Seller will own four million (4,000,000) shares of Common Stock of the Company and the Purchaser will own sixteen million (16,000,000) shares of Common Stock of the Company.
NOW, THEREFORE, for and in consideration of good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the Seller and the Purchaser do hereby agree as follows:
1. Sale of the Shares. Upon the terms of and subject to the conditions of this Agreement, the Seller hereby sells, assigns, transfers and conveys the Shares to the Purchaser, and the Purchaser hereby acquires the Shares from the Seller, free and clear of all liens, encumbrances and restrictions on transfer.
2. Purchase Price. The purchase price for the Shares (the “Purchase Price”) is (i) Two Hundred Thousand Dollars ($200,000.00) (the “Cash Payment”), and (ii) 1,000,000 shares of the common stock of the Purchaser, par value $0.001 per share (the “CELZ Shares”).
3. Closing. The closing of the purchase and sale of the Shares (the “Closing”), shall occur simultaneously with the execution of this Agreement. At the Closing, (a) the Purchaser shall deliver to the Seller the Purchase Price for the Shares, by paying to Seller the Cash Payment and instructing its transfer agent to issue the CELZ Shares to the Seller, and (b) the Seller shall deliver to the Purchaser a Stock Power in the form of Exhibit A attached hereto effecting the transfer of the Shares to the Purchaser.
4. Seller Representations and Warranties. The Seller hereby represents and warrants to the Purchaser as follows:
(i) The Seller is the sole and exclusive owner of the Shares and has good, valid and marketable title to the Shares free and clear of all restrictions, claims, liens, charges, encumbrances and equities whatsoever. The Seller has full right, power and authority to transfer and deliver the Shares to the Purchaser, and hereby transfers to the Purchaser good, valid and marketable title thereto free and clear of any restriction, claim, lien, charge, encumbrance or equity whatsoever.
(ii) The Seller has full power and authority to enter into this Agreement and to consummate the transactions on his part contemplated hereby. Neither the execution and delivery of this Agreement nor the consummation of the transactions herein by the Seller constitutes a violation or breach of applicable law or of any provision of any contract or instrument to which the Seller is a party or by which it is bound, or any order, writ, injunction, decree or judgment applicable to the Seller. The provisions of this Agreement constitute the legal, valid and binding obligations of the Seller enforceable in accordance with their terms.
(iii) The Seller is aware of the Purchaser’s business affairs and financial condition and has acquired sufficient information about the Purchaser to reach an informed and knowledgeable decision to acquire the CELZ Stock. The Seller is acquiring the CELZ Stock for investment for the Seller’s own account only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Securities Act of 1933, as amended (the “Act”).
(iv) The Seller understands that the CELZ Stock has not been registered under the Act by reason of a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Seller’s investment intent as expressed herein.
(v) The Seller acknowledges and understands that the CELZ Stock must be held indefinitely unless the CELZ Stock is subsequently registered under the Act or an exemption from such registration is available. The Seller understands that any certificate evidencing the CELZ Stock will be imprinted with a legend which prohibits the transfer of the CELZ Stock unless the CELZ Stock is registered or such registration is not required in the opinion of counsel for the Purchaser.
1
5. Purchaser Representations and Warranties. The Purchaser hereby represents and warrants to the Seller as follows:
(i) The Purchaser has full power and authority to enter into this Agreement and to consummate the transactions on his part contemplated hereby. Neither the execution and delivery of this Agreement nor the consummation of the transactions herein by the Purchaser constitutes a violation or breach of applicable law or of any provision of any contract or instrument to which the Purchaser is a party or by which it is bound, or any order, writ, injunction, decree or judgment applicable to the Purchaser. The provisions of this Agreement constitute the legal, valid and binding obligations of the Purchaser enforceable in accordance with their terms.
(ii) The Purchaser is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Shares. The Purchaser is acquiring the Shares for investment for the Purchaser’s own account only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Act.
(iii) The Purchaser understands that the Shares have not been registered under the Act by reason of a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Purchaser’s investment intent as expressed herein.
(iv) The Purchaser acknowledges and understands that the Shares must be held indefinitely unless the Shares are subsequently registered under the Act or an exemption from such registration is available. The Purchaser understands that any certificate evidencing the Shares will be imprinted with a legend which prohibits the transfer of the Shares unless the Shares are registered or such registration is not required in the opinion of counsel for the Company.
(v) The Purchaser further understands that at the time the Purchaser wishes to sell the Shares there may be no public market upon which to make such a sale, and that, even if such a public market then exists, the Company may not be satisfying the current public information requirements of Rule 144 promulgated under the Act, and that, in such event, the Purchaser may be precluded from selling the Shares under Rule 144 even if the minimum holding period requirement had been satisfied.
6. Entire Agreement. This Agreement constitutes the entire understanding between the parties with respect to the subject matter hereof and thereof and all prior or contemporaneous agreements, understandings, representations and statements, oral or written, are merged into this Agreement. Neither this Agreement nor any provision hereof may be waived, modified, amended, discharged or terminated except by an instrument in writing signed by the parties hereto.
7. Survival. All covenants, agreements, representations, warranties, indemnities, and obligations set forth in this Agreement shall survive the complete execution, delivery and performance of this Agreement.
8. Binding Effect. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective (as applicable) heirs, executors, administrators, successors and assigns.
9. Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction.
10. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same instrument.
11. Governing Law. This Agreement shall be governed and construed in accordance with the laws of the State of Nevada without giving effect to the choice of law principles thereof.
2
IN WITNESS WHEREOF, the parties hereto have executed this Stock Purchase Agreement effective as of the date first above written.
SELLER:
CREATIVE ACQUISITION CORP.
By: /s/ Timothy Warbington
Name: Timothy Warbington
Title: Chairman and Chief Executive Officer
PURCHASER:
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
By: /s/ Donald Dickerson
Name: Donald Dickerson
Title: Chief Financial Officer
3
STOCK POWER
For Value Received, Creative Acquisition Corp., hereby sells, assigns and transfers unto Creative Medical Technology Holdings, Inc., Four Million (4,000,000) shares of Common Stock of BioDefense, Inc., a Nevada corporation (the “Company”) standing in the undersigned’s name on the books of the Company, and does hereby irrevocably constitute and appoint the Secretary of the Company as Attorney to transfer said stock on the books of the Company with full power of substitution in the premises.
IN WITNESS WHEREOF, Assignor has executed this Stock Power effective as of the date set forth below.
CREATIVE ACQUISITION CORP.
Dated: September 24, 2026 By: /s/ Timothy Warbington
Name: Timothy Warbington
Title: Chairman and Chief Executive Officer
4
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 9
v3.26.3
Cover
Sep. 24, 2026
Cover [Abstract]
Entity Registrant Name
Creative Medical Technology Holdings, Inc.
Entity Central Index Key
0001187953
Document Type
8-K
Amendment Flag
false
Entity Emerging Growth Company
false
Document Period End Date
Sep. 24, 2026
Entity Incorporation State Country Code
NV
Entity File Number
000-53500
Entity Tax Identification Number
87-0622284
Entity Address Address Line 1
211 E Osborn Road
Entity Address City Or Town
Phoenix
Entity Address State Or Province
AZ
Entity Address Postal Zip Code
85012
City Area Code
480
Local Phone Number
399-2822
Written Communications
false
Soliciting Material
false
Pre Commencement Tender Offer
false
Pre Commencement Issuer Tender Offer
false
Security 12b Title
Common Stock, par value $0.001 per share
Trading Symbol
CELZ
Security Exchange Name
NASDAQ
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration